Capricor Therapeutics, Inc.
Financials
Valuation Metrics
Capricor Therapeutics, Inc.'s Market Cap is $419M. At end of 2025 it was $1.41B. Ranked #2843 of 3,118 in US market (top 91%), #1264 of 1,474 on NASDAQ (top 86%), #226 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $419M | US#2,843/3,118 Sec#226/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-129M | US—/3,118 Sec—/265 |
| Total Assets | $369M | US#2,861/3,118 Sec#194/265 |
| Net Assets | $246M | US#2,589/3,118 Sec#170/265 |
| Employees | 231 | US#2,456/3,118 Sec#123/265 |
| Value | ||
| P/B | 1.70x | US#900/3,118 Sec#38/265 |
| EV/EBITDA | 0.42x | US#2/3,118 Sec#1/265 |
| FCF Yield | -30.95% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -52.56% | US#2,685/3,118 Sec#161/265 |
| ROA | -35.10% | US#2,914/3,118 Sec#175/265 |
| Revenue Growth | -100.00% | US#2,725/3,118 Sec#182/265 |
| Financial Health | ||
| Debt Ratio | 49.76% | US#563/3,118 Sec#139/265 |
| Total Debt | $91M | US#2,455/3,118 Sec#126/265 |
| FCF | $-130M | US#2,686/3,118 Sec#165/265 |
| Cash | $21M | US#2,841/3,118 Sec#253/265 |
| Current Ratio | 7.35x | US#334/3,118 Sec#104/265 |
| Net Debt/EBITDA | 0.06x | US#613/3,118 Sec#32/265 |
| Performance | ||
| 1Y Return | 11.21% | US#1,729/3,118 Sec#141/265 |
| 1M Return | -19.11% | US#3,019/3,118 Sec#254/265 |
| From 52W High | -82.07% | US#3,078/3,118 Sec#255/265 |
| 1Y MDD | -89.11% | US#3,099/3,118 Sec#258/265 |
| Trading | ||
| Volume | 4,974,091 shares | US#727/3,118 Sec#59/265 |
| Trading Value | $35M | US#1,969/3,118 Sec#146/265 |
| Per Share | ||
| EPS | $-2.23 | US—/3,118 Sec—/265 |
| BPS | $4.25 | US#2,329/3,118 Sec#134/265 |
Company Info
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.